Form D · Biotechnology

Neopenda, PBC

Chicago, IL · CIK 0001751635

Offering snapshot reported Aug 27, 2026 · SEC filing

Reported sold
$215K
Offering amount: $500K
Investors reported
8
Form D · investor count
Minimum accepted
$5K
Reported outside-investor minimum
First sale
Aug 17, 2026
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Aug 27, 2026Initial$215,000No comparison8SEC filing
May 7, 2026Initial$35,000No comparison1SEC filing
Nov 18, 2024Initial$200,000No comparison1SEC filing
Jan 3, 2024Amendment$700,000$200,000vs Sep 1, 20225SEC filing
Sep 1, 2022Initial$500,000No comparison4SEC filing
Jun 29, 2020Initial$252,000No comparison4SEC filing
Mar 6, 2019Initial$410,000No comparison3SEC filing
Aug 30, 2018Initial$20,000No comparison1SEC filing
Aug 30, 2018Initial$125,000No comparison2SEC filing

Offering details

Securities
Debt
Exemptions
06b
Duration over one year
Yes
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-595567

Source: Form D, filed Aug 27, 2026. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No matching detailed fund disclosure was found in the latest imported ADV filings. This does not establish that the issuer has no adviser.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Teresa Cauvel Director, Executive
Zachary Seaverns Director
Sona Shah Director, Executive

Issuer details

Industry: Biotechnology (See others in industry)

Address:
1623 W Fulton St
Chicago, IL, 60612
Phone: 919-622-2487